Breaking News
Black Friday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?

By Zacks Investment ResearchStock MarketsOct 14, 2019 10:37PM ET
www.investing.com/analysis/can-structural-heart-strength-aid-abbott-abt-q3-earnings-200473572
Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?
By Zacks Investment Research   |  Oct 14, 2019 10:37PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Abbott’s (NYSE:ABT) Structural Heart business has been gaining a strong traction of late on the back of innovations.

We expect this strength to get reflected in third-quarter 2019 results, which are scheduled for release on Oct 16 before the market opens.

Click here to know how the company’s overall Q3 performance is expected to be.

Structural Heart in Focus

Abbott’s Structural Heart business consistently maintained an impressive top-line performance in recent times. The company has been grabbing attention for developments in its flagship, market leading device to treat mitral regurgitation — MitraClip. This upside is likely to reflect on the upcoming quarterly release.

In the last reported quarter, this business witnessed a surge of more than 30% in global sales that also soared above 50% in the United States. With MitraClip’s new expanded indication, we expect this trend to have continued in the third quarter as well. To be precise, in July 2019, Abbott achieved an FDA approval for the fourth-generation MitraClip device with enhanced features and new clip sizes.

Further, in September, the company announced gaining a CE Mark for two new structural heart devices in Europe. These are the Masters HP 15mm rotatable mechanical heart valve and the Amplatzer Piccolo Occluder, both appropriate for treating pediatric heart patients. This pioneering approach to paediatric heart treatment has undoubtedly broadened Abbott’s structural heart portfolio. We expect the company’s top line to reflect this gain in the to-be-reported results.

Additionally, Abbott’s structural heart product line has a robust pipeline of technologies and development including Tendyne and Cephea to replace faulty mitral heart valves. Further, there is TriClip, a first-of-its-kind device for the repair of a leaky tricuspid heart valve, and Amplatzer Amulet, the company’s left atrial appendage device to reduce the risk of stroke in patients with atrial fibrillation. We expect these to have once again registered a strong top-line contribution in the third quarter.

The Zacks Consensus Estimate of $379 million for Structural Heart revenues also indicates a rise of 24.3% from the year-ago reported figure.

Zacks Rank & Stocks to Consider

Abbott carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the same space are as follows:

Akcea Therapeutics, Inc. (NASDAQ:AKCA) has an Earnings ESP of +18.18% and a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has an Earnings ESP of +1.97% and a Zacks Rank #1 (Strong Buy). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has an Earnings ESP of +5.50% and a Zacks Rank of 3.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>



Abbott Laboratories (ABT): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report

Akcea Therapeutics, Inc. (AKCA): Free Stock Analysis Report

Original post

Zacks Investment Research
Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?
 

Related Articles

Anna Coulling
Where Next For Tesla? By Anna Coulling - Nov 26, 2021 1

In the pause point of celebrating Thanksgiving and a four-day weekend, I thought it would be a good time to review some stocks and have decided on the daily chart for Tesla...

Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email